Last reviewed · How we verify
AMDINOCILLIN PIVOXIL
At a glance
| Generic name | AMDINOCILLIN PIVOXIL |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
Key clinical trials
- Prediction and Prevention of Bloodstream Infections After Kidney Transplantation (PHASE2)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women. (PHASE4)
- Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis (PHASE4)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs (PHASE3)
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. (PHASE4)
- Treating Pyelonephritis an Urosepsis With Pivmecillinam (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMDINOCILLIN PIVOXIL CI brief — competitive landscape report
- AMDINOCILLIN PIVOXIL updates RSS · CI watch RSS